MELBOURNE, May 4, 2010 Ansell today announced the launchof their new GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology,at the Annual Congress of the Royal Australasian College of Surgeons inPerth, Australia.
It is the first surgical glove which incorporates a proprietaryantimicrobial coating to provide an additional level of protection tosurgical staff against viruses and bacteria, in the event of a breach duringsurgery.
The last decade has witnessed a rapid expansion of the medical glovesmarket globally. Major drivers for this growth are improving healthcaresystems around the world and the increasing awareness by healthcare workersthat gloves offer an effective protective barrier against contamination frombacteria and viruses. Ansell's new AMT Antimicrobial Technology reducessurgical staff risks of exposure to blood-borne pathogens through a higherlevel of protection.
Extensive in vitro laboratory testing showed that the antimicrobialcoating killed >99 per cent of Hepatitis C1 and 99 percent of HIV-1 (strainMn) within 60 seconds of exposure through a simulated glove breach.
GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology also killsbetween 99.7% to >99.999% of 8 common healthcare infectious bacteria,comprising gram-positive, gram-negative, and drug-resistant bacteria (e.g.MRSA, VRE) within 60 seconds from exposure.
"Ansell's proprietary AMT Antimicrobial surgical glove technology is theresult of intensive and collaborative research, and demonstrates theCompany's ability for industry leading innovation and new productdevelopment", says Magnus Nicolin, CEO of Ansell Ltd.
"It also underscores Ansell's commitment to continuously invest inseeking optimal solutions to better protect healthcare professionals in aworld with an increasing number of high risk pathogens", he continues.
GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology features aunique and proprietary inner coating, containing skin friendly agents andchlorhexidine gluconate (CHG), an effective antimicrobial agent commonlyfound in products such as antiseptics and mouthwash.
Ansell's AMT Antimicrobial Technology is a world first and is now beinglaunched in Australia. It will be progressively rolled out in all Ansellmarkets
1, Tested versus Bovine Viral Diarrhea Virus (BVDV), a common surrogatefor Hepatitis C.
Ansell is a world leader in providing superior health and safetyprotection solutions that enhance human well being. With operations in theAmericas, Europe and Asia Pacific, Ansell employs more than 10,000 peopleworldwide and holds leading market positions in industrial and medicalgloves. Ansell is also a leading player in the household gloves and condommarket segment globally. Information on Ansell and its products can be foundat http://www.ansell.com.
SOURCE Ansell Healthcare